Johnson & Johnson (J&J) has submitted its data to the US FDA (Food and Drug Administration) for emergency use authorization for its booster shot of the J&J COVID-19 vaccination. The submission is based on the Phase 3 ENSEMBLE 2 study that shows that a J&J booster shot given in those 18 years and older 56 days after the first dose gave a 94% protection rate against symptomatic (moderate to severe/critical) COVID-19 in the U.S, and 100% protection against severe/critical COVID-19 after 14 days. This submission follows the data released by J&J reinforcing the efficacy and long-lasting protection of its vaccine.

Learn more here.

More on: